A coordination complex cis-dichlorodiamminedihydroxoplatinum (IV) (
oxoplatinum) was first synthesized in the USSR by Chugaev and Khlopin in 1927 [3]. Its marked antitumor properties were revealed by one of the authors of this article at the All-Union
Cancer Research Center of the Academy of Medical Sciences of the USSR. The paper gives data on the antiblastic and side effects of
oxoplatinum and also on the results of pharmacokinetic studies of the
drug. Particular attention was paid to the similarity and differences of
biological properties of
oxoplatinum and
cis-dichlorodiammineplatinum(II) (DDP) which has found wide use in oncological practice. It has been established that, on principle,
oxoplatinum differs from DDP in action on the body and
tumors. The new
drug is 10 times less toxic than DDP.
Oxoplatinum has a wide spectrum of
antineoplastic action resulting in marked inhibition of growth of solid and ascitic forms of transplantable
tumors. The
drug has a longer duration of antitumor effect after the end of the therapeutic course. An important property of
oxoplatinum is its high therapeutic index. The new
drug manifests high antitumor activity with different ways of its administration into the body.
Oxoplatinum in therapeutic doses does not produce necrotic lesions in the kidneys. The new
drug exerted no cross-resistance with DDP and the alkylating
antitumor agent sarcolysin. At the present time
oxoplatinum is undergoing preclinical investigation.